Sustained	sustained	O	O	O	O
clinical	clinical	O	O	O	O
improvement	improvement	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
decompensated	decompensated	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
virus-related	virus-related	O	O	O	O
cirrhosis	cirrhosis	O	DISEASE	OTHERS	I
after	after	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
monotherapy	monotherapy	O	O	O	O
.	.	O	O	O	O

Hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
virus	virus	O	O	OTHERS	I
(	(	O	O	OTHERS	I
HBV	hbv	O	O	OTHERS	I
)	)	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
causes	causes	O	O	O	O
liver	liver	O	DISEASE	OTHERS	I
cirrhosis	cirrhosis	O	DISEASE	OTHERS	I
and	and	O	O	O	O
hepatocellular	hepatocellular	O	DISEASE	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
,	,	O	O	O	O
remains	remains	O	O	O	O
a	a	O	O	O	O
major	major	O	O	O	O
health	health	O	O	O	O
problem	problem	O	O	O	O
in	in	O	O	O	O
Asian	asian	O	O	O	O
countries	countries	O	O	O	O
.	.	O	O	O	O

Recent	recent	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
vaccine	vaccine	O	O	O	O
for	for	O	O	O	O
prevention	prevention	O	O	O	O
is	is	O	O	O	O
reported	reported	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
successful	successful	O	O	O	O
in	in	O	O	O	O
reducing	reducing	O	O	O	O
the	the	O	O	O	O
size	size	O	O	O	O
of	of	O	O	O	O
chronically	chronically	O	O	O	O
infected	infected	O	O	O	O
carriers	carriers	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
the	the	O	O	O	O
standard	standard	O	O	O	O
medical	medical	O	O	O	O
therapies	therapies	O	O	O	O
have	have	O	O	O	O
not	not	O	O	O	O
been	been	O	O	O	O
established	established	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
now	now	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
this	this	O	O	O	O
report	report	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
encountered	encountered	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
decompensated	decompensated	O	O	O	O
HBV-related	hbv-related	O	O	O	O
cirrhosis	cirrhosis	O	DISEASE	OTHERS	I
who	who	O	O	O	O
exhibited	exhibited	O	O	O	O
the	the	O	O	O	O
dramatic	dramatic	O	O	O	O
improvements	improvements	O	O	O	O
after	after	O	O	O	O
antiviral	antiviral	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
50-year-old	50-year-old	O	O	O	O
woman	woman	O	O	O	O
.	.	O	O	O	O

Previous	previous	O	O	O	O
conventional	conventional	O	O	O	O
medical	medical	O	O	O	O
treatments	treatments	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
effective	effective	O	O	O	O
for	for	O	O	O	O
this	this	O	O	O	O
patient	patient	O	O	O	O
,	,	O	O	O	O
thus	thus	O	O	O	O
this	this	O	O	O	O
patient	patient	O	O	O	O
had	had	O	O	O	O
been	been	O	O	O	O
referred	referred	O	O	O	O
to	to	O	O	O	O
our	our	O	O	O	O
hospital	hospital	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
reverse	reverse	O	O	O	O
transcriptase	transcriptase	O	O	O	O
inhibitor	inhibitor	O	O	O	O
,	,	O	O	O	O
for	for	O	O	O	O
23	23	O	O	O	O
months	months	O	O	O	O
dramatically	dramatically	O	O	O	O
improved	improved	O	O	O	O
her	her	O	O	O	O
liver	liver	O	O	O	O
severity	severity	O	O	O	O
.	.	O	O	O	O

During	during	O	O	O	O
this	this	O	O	O	O
period	period	O	O	O	O
,	,	O	O	O	O
no	no	O	O	O	O
drug	drug	O	O	O	O
resistant	resistant	O	O	O	O
mutant	mutant	O	O	O	O
HBV	hbv	O	O	O	O
emerged	emerged	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
serum	serum	O	O	O	O
HBV-DNA	hbv-dna	O	O	O	O
level	level	O	O	O	O
was	was	O	O	O	O
continuously	continuously	O	O	O	O
suppressed	suppressed	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
virological	virological	O	O	O	O
responses	responses	O	O	O	O
were	were	O	O	O	O
also	also	O	O	O	O
maintained	maintained	O	O	O	O
even	even	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
antiviral	antiviral	O	O	O	O
therapy	therapy	O	O	O	O
was	was	O	O	O	O
discontinued	discontinued	O	O	O	O
.	.	O	O	O	O

Moreover	moreover	O	O	O	O
,	,	O	O	O	O
both	both	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
surface	surface	O	O	OTHERS	I
antigen	antigen	O	O	OTHERS	I
and	and	O	O	O	O
e	e	O	O	OTHERS	I
antigen	antigen	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
to	to	O	O	O	O
have	have	O	O	O	O
disappeared	disappeared	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
patient	patient	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
HBV-related	hbv-related	O	O	O	O
cirrhosis	cirrhosis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
like	like	O	O	O	O
our	our	O	O	O	O
present	present	O	O	O	O
case	case	O	O	O	O
,	,	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
considered	considered	O	O	O	O
as	as	O	O	O	O
an	an	O	O	O	O
initial	initial	O	O	O	O
medical	medical	O	O	O	O
therapeutic	therapeutic	O	O	O	O
option	option	O	O	O	O
,	,	O	O	O	O
especially	especially	O	O	O	O
in	in	O	O	O	O
countries	countries	O	O	O	O
where	where	O	O	O	O
liver	liver	O	O	O	O
transplantation	transplantation	O	O	O	O
is	is	O	O	O	O
not	not	O	O	O	O
reliably	reliably	O	O	O	O
available	available	O	O	O	O
.	.	O	O	O	O

